"The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.
HER2 is a protein involved in normal cell growth. It is foun"...
(Generic versions may still be available.)
Certain signs and symptoms have been reported in association with the use of this drug but, in these instances, it is often impossible to determine the relationship of the underlying disease and drug administration to the reported reaction. Such reactions include maculopapular erythema, increase in blood pressure, paresthesia, malaise, aches and edema of the extremities, glossitis, anorexia, and nausea and vomiting. Alopecia alone and with associated nail growth disturbance have been reported rarely; these side effects subsided without interruption of treatment.
Drug Abuse And Dependence
TESLAC (testolactone) is classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and has been assigned to Schedule III.
Read the Teslac (testolactone) Side Effects Center for a complete guide to possible side effects
When administered concurrently, testolactone may increase the effects of oral anticoagulants; monitor and adjust anticoagulant dosage accordingly.
Drug/Laboratory Test Interactions
Physiologic effects of testolactone may result in decreased estradiol concentrations with radioimmunoassays for estradiol, increased plasma calcium concentrations (see PRECAUTIONS, Laboratory Tests), and increased 24-hour urinary excretion of creatine and 17-ketosteroids.
Last reviewed on RxList: 6/30/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Teslac Information
Report Problems to the Food and Drug Administration
Find support and advances in treatment.